317 related articles for article (PubMed ID: 36894917)
1. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma.
Liu Q; Li R; Wu H; Liang Z
BMC Cancer; 2023 Mar; 23(1):226. PubMed ID: 36894917
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
[TBL] [Abstract][Full Text] [Related]
5. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
6. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
8. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
9. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.
Li S; Chen R; Luo W; Lin J; Chen Y; Wang Z; Lin W; Li B; Wang J; Yang J
Comb Chem High Throughput Screen; 2022; 25(12):2070-2081. PubMed ID: 35048799
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity.
Huang X; Zhou S; Tóth J; Hajdu A
Front Immunol; 2022; 13():978865. PubMed ID: 36090999
[TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
14. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
15. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma.
Yan X; Zheng W; Xu FS; Chang HL; Zhang Y; Zhang ZY; Zhang YH
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2024-2050. PubMed ID: 38497885
[TBL] [Abstract][Full Text] [Related]
17. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Xu QC; Yin XY
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-Related Gene
Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
[TBL] [Abstract][Full Text] [Related]
19. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
20. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma.
Meng Z; Ren D; Zhang K; Zhao J; Jin X; Wu H
Aging (Albany NY); 2020 Mar; 12(6):5048-5070. PubMed ID: 32181755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
